Merus Labs International Inc (MSL.TO) 2.65 $MSL.TO
Merus Labs International Inc. Announces Conversion of $10 Million Convertible Debentures
Marketwire Canada - Thu Jul 17, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has exercised its right to convert the $10 million unsecured convertible debentures (the "Convertible Debentures" issued to a large Canadian institutional investor in September 2013. The Company exercised its right based on the closing price of the Company's common shares having equalled or exceeded $2.30 per share for the 20 consecutive trading days ended July 14, 2014. In aggregate, the Company will issue 6,677,918 common shares to convert the outstanding $10 million principal amount plus accrued but unpaid interest.
Merus Labs International Inc. Announces Closing of $10 Million Preferred Share Financing
Marketwire Canada - Fri Jul 11, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has completed its previously announced private placement issuance of $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. In aggregate, the Company issued 10,000 Series A Preferred Shares at a price of $1,000 per share for total proceeds of $10 million. The proceeds of the offering are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes. Additional details regarding the Series A Preferred Shares are provided in the Company's June 10, 2014 news release.
Merus Signs Definitive Acquisition Agreement With Dacha Strategic Metals Inc.
Marketwire Canada - Fri Jul 04, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) today announced that it has entered into a definitive acquisition agreement with Dacha Strategic Metals Inc. ("Dacha" (TSX VENTURE
SM) pursuant to which Dacha will complete the balance of the previously announced investment of at least $11 million in Merus.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
TSX Venture Exchange Daily Bulletins
CNW Group - Tue Jun 17, 4:00PM CDT
TSX VENTURE COMPANIES:
Merus to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwire Canada - Mon Jun 16, 10:58AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) today announced that Mr. Elie Farah, the President & CEO of Merus, will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference. Mr. Farah's presentation will take place on Wednesday, June 18th, 2014 at 1:30 P.M. (Eastern Time) at the Toronto Board of Trade, 1 First Canadian Place, Toronto, Ontario.
Merus Labs International Inc. Announces Increase to Previously Announced Financing
Marketwire Canada - Thu Jun 12, 9:00AM CDT
Merus Labs International Inc. ("the Company" or "Merus" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce that it has amended the terms of the previously announced bought deal public offering with a syndicate of investment dealers (the "Underwriters" to increase the size of the offering by an additional 3,000,000 common shares (the "Additional Common Shares". Under the amended terms of the offering, the Underwriters have agreed to purchase an aggregate of 16,000,000 common shares ("Common Shares" of the Company for total gross proceeds of $27,200,000.
Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing
Marketwire Canada - Wed Jun 11, 3:20PM CDT
Merus Labs International Inc. ("the Company" or "Merus" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce that it has entered into an agreement with a syndicate of investment dealers (the "Underwriters" pursuant to which the Underwriters have agreed to purchase 13,000,000 common shares ("Shares" from the treasury of the Company, at a price of $1.70 per Share for aggregate gross proceeds of $22,100,000 and offer them to the public by way of prospectus supplement (the "Offering".
Merus Labs International Inc. Announces Aggregate $21 Million Financing Transactions
Marketwire Canada - Tue Jun 10, 3:30PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has entered into a private placement subscription agreement to issue $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. Concurrent with this transaction, Merus has also signed a letter agreement to acquire a new corporation to be incorporated by Dacha Strategic Metals Inc. ("Dacha" (TSX VENTURESM) which upon closing will have approximately $11 million in cash and no other assets or liabilities in exchange for Merus common shares. The $21 million in proceeds from the two financing transactions are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes.
Merus Labs International Inc. Notified of a Canadian ANDS Filing
Marketwire Canada - Tue Jun 03, 4:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) has been notified that Apotex Inc. has filed with Health Canada an Abbreviated New Drug Submission ("ANDS" seeking market approval for a generic version of Enablex(R) (darifenacin hydrobromide tablets) for the Canadian marketplace. The Company received Notices of Allegation against Enablex(R) patents listed on the Canadian patent register which expire in August of 2016 and beyond.
Merus Labs International Inc. Announces Board Appointment
Marketwire Canada - Tue May 27, 7:00AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that it has appointed Theresa Firestone to its board of directors. Mrs. Firestone has over 15 years of experience with Pfizer in Canada, Europe, and Asia. She formerly held positions at Pfizer Canada as the General Manager of the Established Products Business Unit, Vice President of Sales, and Vice President, Government & Public Affairs. Mrs. Firestone also gained international experience while on assignment for Pfizer as the Country Manager of Austria and most recently as the Regional President, Emerging Markets Asia located in Shanghai and Hong Kong. Currently, Mrs. Firestone holds the position of Senior Vice President, Healthcare Businesses at Shoppers Drug Mart Canada.
Merus Labs International Inc. Announces Closing on Full Exercise of Over-Allotment Option
Marketwire Canada - Mon Mar 31, 7:48AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the syndicate of investment dealers (the "Underwriters" has exercised in full the over-allotment option to purchase 1,764,750 common shares of the Company ("Shares" at a price of $1.70 per share granted to the Underwriters in connection with the Company's previously announced public offering which closed on March 25, 2014. The Company has today issued 1,764,750 Shares for additional gross proceeds of $3,000,075 upon closing of the exercise of the over-allotment option.
Merus Labs International Inc.: Completes $20 Million Bought Deal Financing
Marketwire Canada - Tue Mar 25, 7:46AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX:MSL)(NASDAQ:MSLI) is pleased to announce today the closing of its previously announced bought deal financing with a syndicate of investment dealers (the "Underwriters". Under the financing, Merus issued 11,765,000 common shares ("Shares" at a price of $1.70 per Share, for gross proceeds of $20,000,500.
Merus Labs International Inc. Announces $20 Million Bought Deal Financing
Marketwire - Thu Mar 13, 4:22PM CDT
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("the Company" or "Merus" is pleased to announce that it has entered into an agreement with a syndicate of investment dealers (the "Underwriters" pursuant to which the Underwriters have agreed to purchase 11,765,000 common shares ("Shares" from the treasury of the Company, at a price of $1.70 per Share and offer them to the public by way of prospectus supplement (the "Offering".
Merus Labs International Inc. Announces Conversion of $10 Million Convertible Debentures
Marketwire Canada - Thu Jul 17, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has exercised its right to convert the $10 million unsecured convertible debentures (the "Convertible Debentures" issued to a large Canadian institutional investor in September 2013. The Company exercised its right based on the closing price of the Company's common shares having equalled or exceeded $2.30 per share for the 20 consecutive trading days ended July 14, 2014. In aggregate, the Company will issue 6,677,918 common shares to convert the outstanding $10 million principal amount plus accrued but unpaid interest. Merus Labs International Inc. Announces Closing of $10 Million Preferred Share Financing
Marketwire Canada - Fri Jul 11, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has completed its previously announced private placement issuance of $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. In aggregate, the Company issued 10,000 Series A Preferred Shares at a price of $1,000 per share for total proceeds of $10 million. The proceeds of the offering are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes. Additional details regarding the Series A Preferred Shares are provided in the Company's June 10, 2014 news release. Merus Signs Definitive Acquisition Agreement With Dacha Strategic Metals Inc.
Marketwire Canada - Fri Jul 04, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) today announced that it has entered into a definitive acquisition agreement with Dacha Strategic Metals Inc. ("Dacha" (TSX VENTURESM) pursuant to which Dacha will complete the balance of the previously announced investment of at least $11 million in Merus. Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
TSX Venture Exchange Daily Bulletins
CNW Group - Tue Jun 17, 4:00PM CDT
TSX VENTURE COMPANIES:
Merus to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwire Canada - Mon Jun 16, 10:58AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) today announced that Mr. Elie Farah, the President & CEO of Merus, will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference. Mr. Farah's presentation will take place on Wednesday, June 18th, 2014 at 1:30 P.M. (Eastern Time) at the Toronto Board of Trade, 1 First Canadian Place, Toronto, Ontario. Merus Labs International Inc. Announces Increase to Previously Announced Financing
Marketwire Canada - Thu Jun 12, 9:00AM CDT
Merus Labs International Inc. ("the Company" or "Merus"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce that it has amended the terms of the previously announced bought deal public offering with a syndicate of investment dealers (the "Underwriters" to increase the size of the offering by an additional 3,000,000 common shares (the "Additional Common Shares". Under the amended terms of the offering, the Underwriters have agreed to purchase an aggregate of 16,000,000 common shares ("Common Shares" of the Company for total gross proceeds of $27,200,000. Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing
Marketwire Canada - Wed Jun 11, 3:20PM CDT
Merus Labs International Inc. ("the Company" or "Merus"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce that it has entered into an agreement with a syndicate of investment dealers (the "Underwriters" pursuant to which the Underwriters have agreed to purchase 13,000,000 common shares ("Shares" from the treasury of the Company, at a price of $1.70 per Share for aggregate gross proceeds of $22,100,000 and offer them to the public by way of prospectus supplement (the "Offering". Merus Labs International Inc. Announces Aggregate $21 Million Financing Transactions
Marketwire Canada - Tue Jun 10, 3:30PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the Company has entered into a private placement subscription agreement to issue $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. Concurrent with this transaction, Merus has also signed a letter agreement to acquire a new corporation to be incorporated by Dacha Strategic Metals Inc. ("Dacha" (TSX VENTURESM) which upon closing will have approximately $11 million in cash and no other assets or liabilities in exchange for Merus common shares. The $21 million in proceeds from the two financing transactions are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes. Merus Labs International Inc. Notified of a Canadian ANDS Filing
Marketwire Canada - Tue Jun 03, 4:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) has been notified that Apotex Inc. has filed with Health Canada an Abbreviated New Drug Submission ("ANDS" seeking market approval for a generic version of Enablex(R) (darifenacin hydrobromide tablets) for the Canadian marketplace. The Company received Notices of Allegation against Enablex(R) patents listed on the Canadian patent register which expire in August of 2016 and beyond. Merus Labs International Inc. Announces Board Appointment
Marketwire Canada - Tue May 27, 7:00AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that it has appointed Theresa Firestone to its board of directors. Mrs. Firestone has over 15 years of experience with Pfizer in Canada, Europe, and Asia. She formerly held positions at Pfizer Canada as the General Manager of the Established Products Business Unit, Vice President of Sales, and Vice President, Government & Public Affairs. Mrs. Firestone also gained international experience while on assignment for Pfizer as the Country Manager of Austria and most recently as the Regional President, Emerging Markets Asia located in Shanghai and Hong Kong. Currently, Mrs. Firestone holds the position of Senior Vice President, Healthcare Businesses at Shoppers Drug Mart Canada. Merus Labs International Inc. Announces Closing on Full Exercise of Over-Allotment Option
Marketwire Canada - Mon Mar 31, 7:48AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today that the syndicate of investment dealers (the "Underwriters" has exercised in full the over-allotment option to purchase 1,764,750 common shares of the Company ("Shares" at a price of $1.70 per share granted to the Underwriters in connection with the Company's previously announced public offering which closed on March 25, 2014. The Company has today issued 1,764,750 Shares for additional gross proceeds of $3,000,075 upon closing of the exercise of the over-allotment option. Merus Labs International Inc.: Completes $20 Million Bought Deal Financing
Marketwire Canada - Tue Mar 25, 7:46AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) is pleased to announce today the closing of its previously announced bought deal financing with a syndicate of investment dealers (the "Underwriters". Under the financing, Merus issued 11,765,000 common shares ("Shares" at a price of $1.70 per Share, for gross proceeds of $20,000,500. Merus Labs International Inc. Announces $20 Million Bought Deal Financing
Marketwire - Thu Mar 13, 4:22PM CDT
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("the Company" or "Merus"
is pleased to announce that it has entered into an agreement with a syndicate of investment dealers (the "Underwriters" pursuant to which the Underwriters have agreed to purchase 11,765,000 common shares ("Shares" from the treasury of the Company, at a price of $1.70 per Share and offer them to the public by way of prospectus supplement (the "Offering". 
